Windlas Biotech reported Q1 FY27 revenue of INR 248 Cr, up 18% YoY, marking its 14th consecutive quarter of record revenue.

EBITDA (ex-ESOP) grew 26% to INR 34 Cr, with PAT (ex-ESOP) up 37% to INR 25 Cr.

The CDMO vertical revenue surged 29% to INR 207 Cr.

Exports also saw robust 79% growth to INR 11 Cr.

Management expects Plant 6 commercialization by H1 FY27, enhancing capacity.

While Trade Generics faced a temporary dip post-codeine discontinuation, the company is focused on portfolio and geographical expansion.

Management remains confident in disciplined execution, operational efficiencies, and leveraging market opportunities for sustainable long-term growth.